Omeros Corporation
OMER
NASDAQ3.86
Omeros Corporation
NASDAQ:OMER
RECENT
PRICE
3.86
P/E
RATIO
-1.22
(PEG:- -)
P/E RATIO
RELATIVE
TO S&P
-0.06
DIV
YLD
0.00%
High:
Low:
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Legends
Stock price
1.02 Beta (1.0 Market)
0
0
0
0
0
0
0
0
0
% total return 03/23:
Stock
S&P
1y.
0
0
3y.
0
0
5y.
0
0
0
Percent shares traded:
0
0
0
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Fiscal year
0.01
(1.60)
(0.72)
- -
0.13
(1.62)
(1.04)
- -
0.08
(1.67)
(1.39)
- -
0.20
(2.92)
(2.67)
- -
0.10
(1.37)
(1.07)
- -
0.20
(1.29)
(1.21)
- -
0.25
(1.59)
(1.46)
- -
0.06
(1.39)
(1.05)
- -
0.02
(2.22)
(1.75)
- -
0.36
(2.00)
(1.74)
- -
1.03
(1.65)
(1.28)
- -
1.42
(1.17)
(0.80)
- -
0.61
(2.61)
(2.15)
- -
2.26
(1.71)
(1.22)
- -
1.29
(2.41)
(1.76)
- -
- -
3.12
(1.76)
- -
- -
0.76
(1.38)
- -
Revenue per share
Earnings per share
Free Cash Flow per sh
Dividends per share
0.01
- -
0.04
(4.90)
0.01
(6.39)
0.04
5.98
0.39
0.96
0.06
(0.25)
0.03
(0.27)
0.01
(0.64)
0.00
(1.28)
0.01
(0.70)
0.00
(0.93)
0.01
(0.06)
0.01
(2.06)
0.01
(2.20)
0.00
(2.11)
0.00
0.38
0.00
1.37
CAPEX per share
Book Value per share
14
14
14
7
21
22
24
29
33
38
40
46
49
50
57
62
63
Comm.Shares outs.(m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
(2.4)
(0.03)
- -
(5.1)
(0.24)
- -
(3.8)
(0.23)
- -
(5.4)
(0.36)
- -
(4.7)
(0.28)
- -
(6.6)
(0.36)
- -
(9.3)
(0.47)
- -
(7.0)
(0.32)
- -
(14.6)
(0.62)
- -
(6.7)
(0.27)
- -
(9.4)
(0.39)
- -
(5.7)
(0.15)
- -
4.7
0.16
- -
5.8
0.27
- -
Avg. annual P/E ratio
P/E relative to S&P500
Avg. annual div. yield
Capital Structure (31/12/22 | Q4)
Total liabilities
$505 m.
Total assets
$591 m.
Long-term debt
$338 m.
Cash and equiv.
$11 m.
Goodwill - -
Retained earnings $(636) m.
Common stock 63 m. shares
Market Capitalisation
$233 m. (as of 25/3/23)
5
(605.9)%
6
(612.5)%
2
(3,157.3)%
1
(12,988.5)%
14
(527.3)%
42
(130.4)%
65
(67.7)%
30
(375.7)%
112
(56.7)%
74
(149.8)%
- -
(Infinity)%
- -
(Infinity)%
Revenue (m)
Operating margin
0
(29)
0
(38)
0
(40)
0
(74)
0
(75)
0
(67)
1
(53)
1
(127)
2
(84)
2
(138)
1
194
1
47
Depreciation (m)
Net profit (m)
- -
(631.0)%
- -
(638.4)%
- -
(2,487.3)%
- -
(13,668.5)%
- -
(555.9)%
- -
(160.4)%
- -
(82.5)%
9.3%
(424.4)%
- -
(75.6)%
8.0%
(187.0)%
- -
Infinity%
126.0%
Infinity%
Income tax rate
Net profit margin
7
14
(6)
15
20
(7)
3
15
(18)
(9)
26
(43)
21
50
(26)
44
79
(37)
82
83
(3)
53
149
(100)
48
158
(109)
115
236
(121)
196
343
24
307
338
86
Working capital (m)
Long-term debt (m)
Equity (m)
- -
(98.8)%
514.0%
(212.8)%
(138.2)%
588.6%
(802.9)%
(226.4)%
216.5%
956.3%
(633.0)%
172.7%
(218.4)%
(146.0)%
286.3%
(115.1)%
(87.6)%
178.2%
(47.2)%
(36.5)%
1,900.5%
(191.2)%
(128.7)%
126.6%
(75.9)%
(45.1)%
77.5%
(78.6)%
(68.1)%
114.3%
58.2%
51.0%
816.8%
9.1%
(27.0)%
55.3%
ROIC
Return on capital
Return on equity
Working Capital
2020
2021
2022
Cash assets
135
225
135
Receivables
4
82
213
Inventory
1
- -
- -
Other
11
8
35
Current assets
151
248
443
Acc. Payable
4
13
6
Debt due
0
5
99
Other
32
33
32
Current liab.
37
52
136
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
Plowback ratio
Div.&Repurch. to FCF
Omeros Corporation (US) started trading on October 4, 2009 (cik: 0001285819), operates in the Healthcare sector (Biotechnology industry), has 213 full-time employees, and is led by Dr. Gregory A. Demopulos M.D.. Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Annual rates
(avg rate of change)
Past
5 y.
Past
10 y.
Revenues
- -
- -
Cash flow
3.10%
28.25%
Earnings
-71.55%
-10.35%
Dividends
- -
- -
Book value
40.06%
407.02%
Insider trading
Type
Shares
Date
Bumol Thomas F.
Award
7,500
09/21/22
Cable Thomas J.
Award
7,500
09/21/22
Demopulos Peter A Md
Award
7,500
09/21/22
Shah Rajiv
Award
7,500
09/21/22
Zumwalt Kurt
Award
7,500
09/21/22
Fiscal Year Ends
Quarterly Revenue (m)
Full fiscal year
I
II
III
IV
2020
24
14
26
11
74
2021
21
29
30
(80)
(0)
2022
- -
- -
- -
- -
- -
Fiscal Year Ends
Earnings per share
Full fiscal year
I
II
III
IV
2020
(0.51)
(0.58)
(0.67)
(0.65)
-2.41
2021
(0.56)
(0.46)
(0.36)
4.50
3.12
2022
(0.53)
0.17
0.60
0.51
0.76
Fiscal Year Ends
Quarterly dividends paid
Full fiscal year
I
II
III
IV
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -